Simcere Subsidiary, Accused Of Illicitly Producing Substandard Rabies Vaccine, Faces Fine Of RMB 25 Million In China
This article was originally published in PharmAsia News
HONG KONG - Simcere Pharmaceutical Group, maker of innovative drugs and branded generics, has announced disappointing first quarter results, hindered by ongoing difficulties at vaccine maker Jiangsu Yanshen Biological Technology and a sales decline for some traditional best sellers
You may also be interested in...
Investigators Deepen Criminal Probe Into Chinese Vaccine Producer; Regulators Revoke Production License For Rabies Inoculation
BEIJING - Executives at leading Chinese drug maker Simcere Pharmaceutical disclosed that regulators have revoked the production license for a rabies vaccine made by recently acquired Jiangsu Yanshen Biological Technology
While Cementing Partnership With U.S. Biotech Firm, Cash-rich Simcere Launches Twin Acquisitions Targeting Biosimilar, Vaccine Outfits In China
BEIJING - Fresh after cementing a new partnership with a San Francisco-based biologics firm, Simcere Pharmaceutical Group has launched twin acquisitions aimed at simultaneously expanding into the biosimilar and vaccine sectors, according to Simcere's leadership
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).